U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H20N4O
Molecular Weight 320.389
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NIRAPARIB

SMILES

c1cc2cn(-c3ccc(cc3)[C@]4([H])CCCNC4)nc2c(c1)C(=N)O

InChI

InChIKey=PCHKPVIQAHNQLW-CQSZACIVSA-N
InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19873981 | https://www.ncbi.nlm.nih.gov/pubmed/25761096

Niraparib (MK-4827) displays excellent PARP 1 and 2 inhibition. Inhibition of PARP in the context of defects in other DNA repair mechanisms provide a tumor specific way to kill cancer cells. Niraparib is in development with TESARO, under licence from Merck & Co, for the treatment of cancers (ovarian, fallopian tube and peritoneal cancer, breast cancer, prostate cancer and Ewing's sarcoma). Niraparib was characterized in a number of preclinical models before moving to phase I clinical trials, where it showed excellent human pharmacokinetics suitable for once a day oral dosing, achieved its pharmacodynamic target for PARP inhibition, and had promising activity in cancer patients. It is currently being tested in phase 3 clinical trials as maintenance therapy in ovarian cancer and as a treatment for breast cancer.

CNS Activity

Curator's Comment:: Niraparib is able to penetrate the brain in rodents. No human data available.

Originator

Curator's Comment:: # Merck & Co. Inc.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.8 nM [IC50]
2.1 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZEJULA

Approved Use

ZEJULA is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Launch Date

1.49048643E12
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
803.7 ng/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIRAPARIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
804 ng/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIRAPARIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
29016.1 ng × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIRAPARIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
50.5 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIRAPARIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
17%
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIRAPARIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 59 years (range: 39–75 years)
n = 6
Health Status: unhealthy
Condition: advanced solid tumours
Age Group: 59 years (range: 39–75 years)
Sex: M+F
Population Size: 6
Sources:
DLT: Thrombocytopenia...
Other AEs: Neutropenia, Neutropenia...
Dose limiting toxicities:
Thrombocytopenia (grade 4, 2 patients)
Other AEs:
Neutropenia (grade 1-2, 3 patients)
Neutropenia (grade 3, 1 patient)
Lymphopenia (grade 3, 1 patient)
Nausea (grade 1-2, 3 patients)
Vomiting (grade 1-2, 3 patients)
Constipation (grade 1-2, 2 patients)
Anorexia (grade 1-2, 2 patients)
Fatigue (grade 1-2, 4 patients)
Insomnia (grade 1-2, 2 patients)
Sources:
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 59 years (range: 39–75 years)
n = 6
Health Status: unhealthy
Condition: advanced solid tumours
Age Group: 59 years (range: 39–75 years)
Sex: M+F
Population Size: 6
Sources:
DLT: Fatigue...
Dose limiting toxicities:
Fatigue (grade 3, 1 patient)
Sources:
60 mg 1 times / day steady, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
unhealthy, 59 years (range: 39–75 years)
n = 7
Health Status: unhealthy
Condition: advanced solid tumours
Age Group: 59 years (range: 39–75 years)
Sex: M+F
Population Size: 7
Sources:
DLT: Pneumonitis...
Dose limiting toxicities:
Pneumonitis (grade 3, 1 patient)
Sources:
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Disc. AE: Thrombocytopenia, Anemia...
Other AEs: Thrombocytopenia, Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (3%)
Anemia (1%)
Neutropenia (2%)
Hypertension (<1%)
Myelodysplastic syndrome (grade 5, 1 patient)
Other AEs:
Thrombocytopenia (grade 1-2, 32%)
Thrombocytopenia (grade 3-4, 29%)
Anemia (grade 1-2, 25%)
Anemia (grade 3-4, 25%)
Neutropenia (grade 1-2, 10%)
Neutropenia (grade 3-4, 20%)
Leukopenia (grade 1-2, 12%)
Leukopenia (grade 3-4, 5%)
Palpitations (grade 1-2, 10%)
Nausea (grade 1-2, 71%)
Nausea (grade 3-4, 3%)
Abdominal distension (grade 1-2, 31%)
Abdominal distension (grade 3-4, 2%)
Vomiting (grade 1-2, 32%)
Vomiting (grade 3-4, 2%)
Constipation (grade 1-2, 39.2%)
Constipation (grade 3-4, 0.8%)
Mucositis (grade 1-2, 19.5%)
Mucositis (grade 3-4, 0.5%)
Stomatitis (grade 1-2, 19.5%)
Stomatitis (grade 3-4, 0.5%)
Diarrhea (grade 1-2, 19.7%)
Diarrhea (grade 3-4, 0.3%)
Dyspepsia (grade 1-2, 18%)
Dry mouth (grade 1-2, 9.7%)
Dry mouth (grade 3-4, 0.3%)
Fatigue (grade 1-2, 49%)
Fatigue (grade 1-2, 49%)
Asthenia (grade 3-4, 8%)
Asthenia (grade 3-4, 8%)
Decreased appetite (grade 1-2, 24.7%)
Decreased appetite (grade 3-4, 0.3%)
Urinary tract infection (grade 1-2, 12.2%)
Urinary tract infection (grade 3-4, 0.8%)
Aspartate aminotransferase increased (grade 1-2, 6%)
Aspartate aminotransferase increased (grade 3-4, 4%)
Alanine aminotransferase increase (grade 1-2, 6%)
Alanine aminotransferase increase (grade 3-4, 4%)
Myalgia (grade 1-2, 18.2%)
Myalgia (grade 3-4, 0.8%)
Back pain (grade 1-2, 17.2%)
Back pain (grade 3-4, 0.8%)
Arthralgia (grade 1-2, 12.7%)
Arthralgia (grade 3-4, 0.3%)
Headache (grade 1-2, 25.7%)
Headache (grade 3-4, 0.3%)
Dizziness (grade 1-2, 18%)
Dysgeusia (grade 1-2, 10%)
Insomnia (grade 1-2, 26.7%)
Insomnia (grade 3-4, 0.3%)
Anxiety (grade 1-2, 10.7%)
Anxiety (grade 3-4, 0.3%)
Nasopharyngitis (grade 1-2, 23%)
Dyspnea (grade 1-2, 19%)
Dyspnea (grade 3-4, 1%)
Cough (grade 1-2, 16%)
Rash (grade 1-2, 20.5%)
Rash (grade 3-4, 0.5%)
Hypertension (grade 1-2, 11%)
Hypertension (grade 3-4, 9%)
Decreased hemoglobin (grade 1-2, 60%)
Decreased hemoglobin (grade 3-4, 25%)
Platelet count decreased (grade 1-2, 37%)
Platelet count decreased (grade 3-4, 35%)
WBC decreased (grade 1-2, 59%)
WBC decreased (grade 3-4, 7%)
Absolute neutrophil count decreased (grade 1-2, 32%)
Absolute neutrophil count decreased (grade 3-4, 21%)
Myelodysplastic syndrome (all grades, 1.4%)
Tachycardia (1-10)
Peripheral edema (1-10)
Hypokalemia (1-10)
Bronchitis (1-10)
Conjunctivitis (1-10)
Gamma-glutamyltransferase increased (1-10)
Blood creatinine increased (1-10)
Blood alkaline phosphatase increased (1-10)
Weight decreased (1-10)
Depression (1-10)
Epistaxis (1-10)
Sources:
AEs

AEs

AESignificanceDosePopulation
Anorexia grade 1-2, 2 patients
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 59 years (range: 39–75 years)
n = 6
Health Status: unhealthy
Condition: advanced solid tumours
Age Group: 59 years (range: 39–75 years)
Sex: M+F
Population Size: 6
Sources:
Constipation grade 1-2, 2 patients
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 59 years (range: 39–75 years)
n = 6
Health Status: unhealthy
Condition: advanced solid tumours
Age Group: 59 years (range: 39–75 years)
Sex: M+F
Population Size: 6
Sources:
Insomnia grade 1-2, 2 patients
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 59 years (range: 39–75 years)
n = 6
Health Status: unhealthy
Condition: advanced solid tumours
Age Group: 59 years (range: 39–75 years)
Sex: M+F
Population Size: 6
Sources:
Nausea grade 1-2, 3 patients
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 59 years (range: 39–75 years)
n = 6
Health Status: unhealthy
Condition: advanced solid tumours
Age Group: 59 years (range: 39–75 years)
Sex: M+F
Population Size: 6
Sources:
Neutropenia grade 1-2, 3 patients
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 59 years (range: 39–75 years)
n = 6
Health Status: unhealthy
Condition: advanced solid tumours
Age Group: 59 years (range: 39–75 years)
Sex: M+F
Population Size: 6
Sources:
Vomiting grade 1-2, 3 patients
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 59 years (range: 39–75 years)
n = 6
Health Status: unhealthy
Condition: advanced solid tumours
Age Group: 59 years (range: 39–75 years)
Sex: M+F
Population Size: 6
Sources:
Fatigue grade 1-2, 4 patients
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 59 years (range: 39–75 years)
n = 6
Health Status: unhealthy
Condition: advanced solid tumours
Age Group: 59 years (range: 39–75 years)
Sex: M+F
Population Size: 6
Sources:
Lymphopenia grade 3, 1 patient
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 59 years (range: 39–75 years)
n = 6
Health Status: unhealthy
Condition: advanced solid tumours
Age Group: 59 years (range: 39–75 years)
Sex: M+F
Population Size: 6
Sources:
Neutropenia grade 3, 1 patient
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 59 years (range: 39–75 years)
n = 6
Health Status: unhealthy
Condition: advanced solid tumours
Age Group: 59 years (range: 39–75 years)
Sex: M+F
Population Size: 6
Sources:
Thrombocytopenia grade 4, 2 patients
DLT, Disc. AE
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 59 years (range: 39–75 years)
n = 6
Health Status: unhealthy
Condition: advanced solid tumours
Age Group: 59 years (range: 39–75 years)
Sex: M+F
Population Size: 6
Sources:
Fatigue grade 3, 1 patient
DLT
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 59 years (range: 39–75 years)
n = 6
Health Status: unhealthy
Condition: advanced solid tumours
Age Group: 59 years (range: 39–75 years)
Sex: M+F
Population Size: 6
Sources:
Pneumonitis grade 3, 1 patient
DLT
60 mg 1 times / day steady, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
unhealthy, 59 years (range: 39–75 years)
n = 7
Health Status: unhealthy
Condition: advanced solid tumours
Age Group: 59 years (range: 39–75 years)
Sex: M+F
Population Size: 7
Sources:
Anemia 1%
Disc. AE
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Blood alkaline phosphatase increased 1-10
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Blood creatinine increased 1-10
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Bronchitis 1-10
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Conjunctivitis 1-10
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Depression 1-10
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Epistaxis 1-10
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Gamma-glutamyltransferase increased 1-10
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Hypokalemia 1-10
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Peripheral edema 1-10
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Tachycardia 1-10
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Weight decreased 1-10
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Neutropenia 2%
Disc. AE
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Thrombocytopenia 3%
Disc. AE
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Hypertension <1%
Disc. AE
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Myelodysplastic syndrome all grades, 1.4%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Dysgeusia grade 1-2, 10%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Neutropenia grade 1-2, 10%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Palpitations grade 1-2, 10%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Anxiety grade 1-2, 10.7%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Hypertension grade 1-2, 11%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Leukopenia grade 1-2, 12%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Urinary tract infection grade 1-2, 12.2%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Arthralgia grade 1-2, 12.7%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Cough grade 1-2, 16%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Back pain grade 1-2, 17.2%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Dizziness grade 1-2, 18%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Dyspepsia grade 1-2, 18%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Myalgia grade 1-2, 18.2%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Dyspnea grade 1-2, 19%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Mucositis grade 1-2, 19.5%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Stomatitis grade 1-2, 19.5%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Diarrhea grade 1-2, 19.7%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Rash grade 1-2, 20.5%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Nasopharyngitis grade 1-2, 23%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Decreased appetite grade 1-2, 24.7%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Anemia grade 1-2, 25%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Headache grade 1-2, 25.7%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Insomnia grade 1-2, 26.7%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Abdominal distension grade 1-2, 31%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Absolute neutrophil count decreased grade 1-2, 32%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Thrombocytopenia grade 1-2, 32%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Vomiting grade 1-2, 32%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Platelet count decreased grade 1-2, 37%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Constipation grade 1-2, 39.2%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Fatigue grade 1-2, 49%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Fatigue grade 1-2, 49%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
WBC decreased grade 1-2, 59%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Alanine aminotransferase increase grade 1-2, 6%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Aspartate aminotransferase increased grade 1-2, 6%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Decreased hemoglobin grade 1-2, 60%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Nausea grade 1-2, 71%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Dry mouth grade 1-2, 9.7%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Anxiety grade 3-4, 0.3%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Arthralgia grade 3-4, 0.3%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Decreased appetite grade 3-4, 0.3%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Diarrhea grade 3-4, 0.3%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Dry mouth grade 3-4, 0.3%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Headache grade 3-4, 0.3%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Insomnia grade 3-4, 0.3%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Mucositis grade 3-4, 0.5%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Rash grade 3-4, 0.5%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Stomatitis grade 3-4, 0.5%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Back pain grade 3-4, 0.8%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Constipation grade 3-4, 0.8%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Myalgia grade 3-4, 0.8%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Urinary tract infection grade 3-4, 0.8%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Dyspnea grade 3-4, 1%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Abdominal distension grade 3-4, 2%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Vomiting grade 3-4, 2%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Neutropenia grade 3-4, 20%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Absolute neutrophil count decreased grade 3-4, 21%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Anemia grade 3-4, 25%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Decreased hemoglobin grade 3-4, 25%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Thrombocytopenia grade 3-4, 29%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Nausea grade 3-4, 3%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Platelet count decreased grade 3-4, 35%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Alanine aminotransferase increase grade 3-4, 4%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Aspartate aminotransferase increased grade 3-4, 4%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Leukopenia grade 3-4, 5%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
WBC decreased grade 3-4, 7%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Asthenia grade 3-4, 8%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Asthenia grade 3-4, 8%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Hypertension grade 3-4, 9%
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
Myelodysplastic syndrome grade 5, 1 patient
Disc. AE
300 mg 1 times / day steady, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 367
Health Status: unhealthy
Condition: platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer
Population Size: 367
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
weak [Inhibition 161 uM]
weak
weak
yes [IC50 1.21 uM]
yes [Inhibition 0.18 uM]
yes [Inhibition <0.14 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
Tox targets

Tox targets

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
2005 Apr 14
Patents

Sample Use Guides

Niraparib (PO, 110-210 mg) successfully inhibited poly(ADP-ribose) polymerase (PARP) during a phase I trial in patients with BRCA-deficient or sporadic cancers associated with homologous recombination repair defects. Niraparib (PO, 30-210 mg) was well tolerated during a phase I trial in patients with BRCA-deficient or sporadic cancers associated with homologous recombination repair defects. Maximum tolerated dose (MTD) of niraparib in patients with advanced solid tumours was 300 mg.
Route of Administration: Oral
Niraparib (MK-4827) inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC(50) in the 10-100 nM range.
Name Type Language
NIRAPARIB
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
JNJ-64091742
Code English
NIRAPARIB [MI]
Common Name English
MK-4827
Code English
2-(4-((3S)-PIPERIDIN-3-YL)PHENYL)-2H-INDAZOLE-7-CARBOXAMIDE
Systematic Name English
ZL-2306
Code English
NIRAPARIB [WHO-DD]
Common Name English
NIRAPARIB [USAN]
Common Name English
2H-INDAZOLE-7-CARBOXAMIDE, 2-(4-(3S)-3-PIPERIDINYLPHENYL)-
Systematic Name English
MK4827
Code English
NIRAPARIB [INN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000191623
Created by admin on Sat Jun 26 06:04:24 UTC 2021 , Edited by admin on Sat Jun 26 06:04:24 UTC 2021
FDA ORPHAN DRUG 306510
Created by admin on Sat Jun 26 06:04:24 UTC 2021 , Edited by admin on Sat Jun 26 06:04:24 UTC 2021
WHO-ATC L01XX54
Created by admin on Sat Jun 26 06:04:24 UTC 2021 , Edited by admin on Sat Jun 26 06:04:24 UTC 2021
NCI_THESAURUS C62554
Created by admin on Sat Jun 26 06:04:24 UTC 2021 , Edited by admin on Sat Jun 26 06:04:24 UTC 2021
Code System Code Type Description
MERCK INDEX
M11995
Created by admin on Sat Jun 26 06:04:24 UTC 2021 , Edited by admin on Sat Jun 26 06:04:24 UTC 2021
PRIMARY
EPA CompTox
1038915-60-4
Created by admin on Sat Jun 26 06:04:24 UTC 2021 , Edited by admin on Sat Jun 26 06:04:24 UTC 2021
PRIMARY
NCI_THESAURUS
C80059
Created by admin on Sat Jun 26 06:04:24 UTC 2021 , Edited by admin on Sat Jun 26 06:04:24 UTC 2021
PRIMARY
WIKIPEDIA
NIRAPARIB
Created by admin on Sat Jun 26 06:04:24 UTC 2021 , Edited by admin on Sat Jun 26 06:04:24 UTC 2021
PRIMARY
FDA UNII
HMC2H89N35
Created by admin on Sat Jun 26 06:04:24 UTC 2021 , Edited by admin on Sat Jun 26 06:04:24 UTC 2021
PRIMARY
PUBCHEM
24958200
Created by admin on Sat Jun 26 06:04:24 UTC 2021 , Edited by admin on Sat Jun 26 06:04:24 UTC 2021
PRIMARY
ChEMBL
CHEMBL1094636
Created by admin on Sat Jun 26 06:04:24 UTC 2021 , Edited by admin on Sat Jun 26 06:04:24 UTC 2021
PRIMARY
DRUG CENTRAL
5222
Created by admin on Sat Jun 26 06:04:24 UTC 2021 , Edited by admin on Sat Jun 26 06:04:24 UTC 2021
PRIMARY
DRUG BANK
DB11793
Created by admin on Sat Jun 26 06:04:24 UTC 2021 , Edited by admin on Sat Jun 26 06:04:24 UTC 2021
PRIMARY
CAS
1038915-60-4
Created by admin on Sat Jun 26 06:04:24 UTC 2021 , Edited by admin on Sat Jun 26 06:04:24 UTC 2021
PRIMARY
RXCUI
1918231
Created by admin on Sat Jun 26 06:04:24 UTC 2021 , Edited by admin on Sat Jun 26 06:04:24 UTC 2021
PRIMARY
EVMPD
SUB177208
Created by admin on Sat Jun 26 06:04:24 UTC 2021 , Edited by admin on Sat Jun 26 06:04:24 UTC 2021
PRIMARY
LACTMED
Niraparib
Created by admin on Sat Jun 26 06:04:24 UTC 2021 , Edited by admin on Sat Jun 26 06:04:24 UTC 2021
PRIMARY
INN
9526
Created by admin on Sat Jun 26 06:04:24 UTC 2021 , Edited by admin on Sat Jun 26 06:04:24 UTC 2021
PRIMARY